Annexon Inc
NASDAQ:ANNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (19.1), the stock would be worth $-26.71 (553% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.2 | $5.89 |
0%
|
| Industry Average | 19.1 | $-26.71 |
-553%
|
| Country Average | 22.9 | $-31.93 |
-642%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
$821.5m
|
/ |
Jan 2026
$-208.5m
|
= |
|
|
$821.5m
|
/ |
Dec 2026
$-182.3m
|
= |
|
|
$821.5m
|
/ |
Dec 2027
$-135.9m
|
= |
|
|
$821.5m
|
/ |
Dec 2028
$21.7m
|
= |
|
|
$821.5m
|
/ |
Dec 2029
$248.8m
|
= |
|
|
$821.5m
|
/ |
Dec 2030
$447.7m
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| US |
|
Annexon Inc
NASDAQ:ANNX
|
879.7m USD | -4.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.6B AUD | 29.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 15.3 |
| Median | 22.9 |
| 70th Percentile | 33.2 |
| Max | 1 826 183.3 |
Other Multiples
Annexon Inc
Glance View
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 61 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Its pipeline includes three clinical-stage assets across three therapeutic franchises: Autoimmune, Neurodegeneration and Ophthalmology. Its lead candidate, ANX005, is a monoclonal antibody formulated for intravenous administration for several autoimmune indications. ANX005 is being evaluated in a Phase II/III clinical trial for the treatment of patients with Guillain-Barre Syndrome and a Phase II trial in patients with warm autoimmune hemolytic anemia. The company ANX009 clinical candidate is a subcutaneous formulation of an antigen-binding fragment, which is evaluates in a Phase I trial. The company is also developing ANX005, which is in Phase II trials in Huntington’s disease and amyotrophic lateral sclerosis. The firm's ANX007 program is a Fab formulated.
